Navigation Links
LSUHSC awarded patent for compound inhibiting cancer and other diseases
Date:10/6/2008

New Orleans, LA Dr. Eugene Woltering, the James D. Rives Professor of Surgery and Neurosciences at LSU Health Sciences Center New Orleans School of Medicine, and Dr. Conrad Hornick, former LSUHSC Professor of Physiology, have been awarded a US Patent for a compound to inhibit the formation of blood vessels critical to the growth of cancerous tumors and diseases like diabetic retinopathy, obesity, and psoriasis.

Apolipoprotein A-I is the major protein component of lipoproteins water soluble carrier molecules that transport cholesterol through the blood. LSUHSC researchers discovered that it can be used to destroy existing blood vessels as well as prevent the development of new vessels. For a tumor to grow bigger than 2 mm, the diameter of a large grain of sand, it must a have blood supply. Application of Apoliporpotein A-1 and high density lipoprotein has been proven effective in inhibiting tumor growth dependent upon angiogenesisthe process of developing new blood vessels. Studies have demonstrated that the level of vascularization in a tumor is strongly associated with metastasis in melanoma, breast, and lung carcinomas.

"This patent was based on the observation that lipid droplets are critical to the formation of the lumen of the blood vessels. By removing these fat droplets from the developing blood vessel we feel that we will be able to control the growth of new blood vessels that would feed tumors," notes Dr. Woltering.

There is also evidence that Apolipoprotein A-1 will be effective in treating other diseases reliant upon angiogenesis. In those diseases, angiogenesis is the root cause of tissue injury, including blindness associated with proliferative retinopathies, skin disorders such as psoriasis, and rheumatoid arthritis. Diseases that have been associated with abnormal blood vessel formation include Crohn's disease, diabetic retinopathy, macular degeneration, obesity, corneal neovascularization, benign tumors,
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-452-9166
Louisiana State University Health Science Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. LSUHSC awarded $10M+ COBRE grant
2. LSUHSCs Lazartigues awarded $1.2 million grant
3. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
4. 12 McGill researchers awarded Canada Research Chairs
5. Anthony S. Fauci awarded Lasker Award for Public Service
6. ETH Zurich professor Ari Helenius awarded Benoist Prize
7. Nanobiosym awarded $2 million DTRA contract
8. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
9. Parus Interactive Awarded Patent for Speech-Activated Remote System Management
10. $2.7 million awarded for metastatic colon cancer research
11. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... have discovered the "molecular brakes" that time the generation ... mice. These "hair cells" translate sound waves into electrical ... interpreted as sounds. If the arrangement of the cells ... of the research will be published in The ... proteins Hey1 and Hey2 act as brakes to prevent ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
(Date:9/16/2014)... species has its own bacterial identity. That,s the conclusion ... institutions who studied the genetic fingerprints of bacteria on ... , "This study demonstrates for the first time that ... ecological strategies possess very different microbial communities on their ... postdoctoral researcher in the UO,s Institute of Ecology and ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2
... Future of the Nuclear Industry" will be the Plenary Session topic ... taking place June 28-July 1, 2010, at the Salt Palace Convention ... Chair of the Nuclear Regulatory Commission, will be the lead presenter ... Over 250 presentations between June 28 and July 1 will occur ...
... been established for more than 50 years as one ... termed bipolar disorder. However, scientists have never been ... new research from Cardiff University scientists suggests a possible ... better understanding of the illness and potentially more effective ...
... bacteria lead oil companies to change their methods of harvesting ... reducing the carbon dioxide that burning oil and gasoline discharges ... Larter, professor of geoscience and holder of the ... Calgary, was the keynote speaker today for the 2010 Goldschmidt ...
Cached Biology News:55th annual meeting of the Health Physics Society 2
(Date:9/17/2014)... FORT LAUDERDALE, Fla. , Sept. 17, 2014 ... signed an agreement to form a Special Purpose Vehicle in ... based Jatropha centric agro energy company. The SPV shall ... U.S. registered entity with AFAI as majority shareholder. The SPV ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... Cary, N.C. (PRWEB) September 17, 2014 ... solutions that advances science and healthcare, has renewed its ... term. , As part of the agreement, Personify will ... with a sustained emphasis on recruitment analytics, including time-to-fill, ... decision to renew our agreement with Personify was based ...
(Date:9/17/2014)... 2014 The Alliance for ... multi-stakeholder non-profit collaborative building a global system to ... today announced Phase 3 of its Site Accreditation ... Amir H. Kalali, Vice-President, Global Head, Neuroscience Center ... Compliance and Quality Integration (CQI) Consulting will lead ...
(Date:9/16/2014)... D.C., September 16, 2014 --The emerging field of ... to the next level, enabling the construction of ... efficient devices, individual molecules would take on the ... transistors. , A team of researchers from five ... candidate for use in small-scale electronics: a molecule ...
Breaking Biology Technology:AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4The future face of molecular electronics 2
... The world,s smallest chess board about the diameter ... were winners in this year,s design contest for, respectively, ... National Laboratories in mid May. The two winning ... facility, one of the most advanced in the world. ...
... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer ... its AspirinWorks® Test June 17-19 at the Pri-Med New York ... Convention Center in New York, N.Y. , ... Corgenix representatives will be on-hand during the conference ...
... New data from a retrospective cohort study showed that up ... (GID) that can have a substantial adverse effect on major PD-related clinical ... Congress of Parkinson,s Disease and Movement Disorders in Buenos Aires, Argentina ... , , ...
Cached Biology Technology:Texas Tech, U of Utah win Sandia microdevice competition 2Texas Tech, U of Utah win Sandia microdevice competition 3Texas Tech, U of Utah win Sandia microdevice competition 4Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York 2Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 2New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 4
...
...
... The pCITE-2a-c(+) vectors are designed for enhanced translation ... extracts, e.g. rabbit reticulocyte lysate. The maps for ... with the following exceptions: pCITE-2b(+) is a 3793 ... BstX I and Xcm I sites. Subtract 7 ...
...
Biology Products: